Skip to main content

GeneNews Inks China Marketing Agreement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GeneNews said today that it has reached a term sheet agreement with GeneDiagnostics for the marketing of its colorectal cancer risk test in parts of China.

Toronto-based GeneNews said that it expects to finalize a formal marketing partnership agreement with the Chinese firm before the end of its current fiscal quarter.

The agreement would give GeneDiagnostics non-exclusive rights to market the ColonSentry blood-based test, which uses biomarkers to determine a person's current risk for colorectal cancer, in Shanghai and in the provinces of Zhejiang and Jiangsu. These regions include a combined total of more than 38 million men and women aged 50 or older.

"The engagement of additional partners to establish a global ColonSentry marketing and distribution network is a key objective for GeneNews in 2010 and the signing of this binding term sheet with GeneDiagnostics is an important step towards achieving that goal," GeneNews President and COO Gailina Liew said in a statement.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.